Skip to main content
Caplight Logo









Delve Bio

Delve Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.delve.bio/

Last Round

Series A

Jun 20, 2023

Total Funding Raised

$35M

Company Overview

Delve Bio is a biotechnology company that provides a metagenomic next-generation sequencing (mNGS) platform for the unbiased detection of neuro-infectious pathogens in cerebrospinal fluid.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

metagenomic next-generation sequencingmNGSinfectious disease diagnosticsneurological infectionsclinical diagnosticspathogen identificationbioinformatics pipelineclinical sequencingprecision medicinepathogen detectionnext-gen sequencingdiagnostic testingpathogenomicsclinical genomicsmolecular diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delve Bio Comparables

Compare Delve Bio with similar companies based on industry and business-model similarity.

Delve Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Karius
80%
Biotia
79%
bioMérieux
79%

Delve Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2023

Key People

Founding team and executive leadership

Bradley Murray

CEO And Co-Founder

Founding Team

Delve Bio Investors

Notable investors and investment history

Delve Bio investors
InvestorRounds
S32Series A
GVSeries A
Perceptive AdvisorsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 83% MoM, reaching 7.2K.

  • Jan 1, 2024

    Flagship platform Delve Detect to launch in 2024.

Delve Bio Filings

Explore SEC and related filing metadata, where available.

Delve Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Delve Bio's valuation, stock price, and market status.

Is Delve Bio a public or private company?

Delve Bio is a private company.

What is the current stock price of Delve Bio?

Delve Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Delve Bio worth (valuation)?

Valuation information for Delve Bio is not publicly available.

Can I buy Delve Bio stock?

Delve Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Delve Bio's last funding round?

Delve Bio's most recent funding round was Series A on June 20, 2023.

Who are the main investors in Delve Bio?

Key investors in Delve Bio include Perceptive Advisors.

Will Delve Bio IPO soon?

No public IPO plans have been announced for Delve Bio.

How can I track Delve Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Delve Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range33
Year Founded2022
Last FundingJun 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?